Recursion focuses on diseases where there is a high unmet need – including aggressive cancers and rare diseases. The company is already seeing encouraging data for some of its clinical programs ...

Sourcetree tutorial with Git and Bitbucket Git isn’t hard to learn. Moreover, with a Git GUI such as Atlassian’s Sourcetree, and a SaaS code repository such as Bitbucket, mastery of the industry’s ...

Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.

Apache Struts is one of the most popular web development frameworks in the history of the Java language, and the Eclipse IDE remains one of the most popular Java IDEs on the market. As such, it only ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 5, Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc ...

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Find annual and quearterly earnings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) including earnings per share, earnings forecasts at Nasdaq.com.

Stay up-to-date on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.